Smithbridge Asset Management Inc. DE Has $4.79 Million Position in Abbott Laboratories $ABT

Smithbridge Asset Management Inc. DE lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 47.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,633 shares of the healthcare product maker’s stock after selling 41,457 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Abbott Laboratories were worth $4,788,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Freemont Management S.A. grew its position in Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $116,580,000. Danica Pension Livsforsikringsaktieselskab bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth approximately $185,640,000. Thrivent Financial for Lutherans grew its holdings in shares of Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares in the last quarter. Finally, Net Worth Advisory Group bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $1,366,000. Institutional investors own 75.18% of the company’s stock.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ABT has been the subject of several research reports. Benchmark reduced their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Citigroup lowered their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research note on Wednesday, April 22nd. Argus decreased their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Finally, Royal Bank Of Canada lowered their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.42.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $92.15 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The business’s fifty day moving average price is $88.83 and its two-hundred day moving average price is $104.62. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The stock has a market capitalization of $160.51 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 1.56 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period last year, the business earned $1.09 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. Abbott Laboratories’s payout ratio is 70.59%.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Robert W. Baird initiated coverage on Abbott Laboratories with an Outperform rating and a $121 price target, signaling strong upside potential and renewed Wall Street confidence. Article Title
• Positive Sentiment: Tandem Diabetes Care launched compatibility for its t:slim X2 insulin pump with Abbott’s FreeStyle Libre 3 Plus sensor in five international markets, which could expand Abbott’s CGM ecosystem and support diabetes-care sales. Article Title
• Positive Sentiment: Wells Fargo reiterated a Buy rating on Abbott Laboratories, adding to the positive analyst sentiment around the stock. Article Title
• Positive Sentiment: TipRanks highlighted Abbott as one of the dividend aristocrats that Wall Street currently likes, reinforcing the view that it remains a favored defensive healthcare name. Article Title
• Neutral Sentiment: Recent coverage compared Abbott with Intuitive Surgical, but the article was more of a broader healthcare-stock debate than a direct catalyst for Abbott’s shares. Article Title
• Neutral Sentiment: Abbott-related commentary on multi-cancer blood screening and broader healthcare trends is informative for the sector, but it does not appear to be a direct company-specific catalyst. Article Title
• Negative Sentiment: Abbott also faced headlines about a closed U.S. criminal probe into its infant-formula plant and a proposed civil settlement, which could remain a legal overhang even if the worst-case risk has eased. Article Title

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.